Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial.

Publication ,  Journal Article
Herrmann, HC; Gertz, ZM; Silvestry, FE; Wiegers, SE; Woo, YJ; Hermiller, J; Segar, D; Heimansohn, D; Gray, W; Homma, S; Argenziano, M; Wang, A ...
Published in: J Am Coll Cardiol
April 3, 2012

OBJECTIVES: The purpose of this study was to characterize patients with mitral regurgitation (MR) and atrial fibrillation (AF) treated percutaneously using the MitraClip device (Abbott Vascular, Abbott Park, Illinois) and compare the results with surgery in this population. BACKGROUND: The EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized controlled trial compared a less invasive catheter-based treatment for MR with surgery, providing an opportunity to assess the impact of AF on the outcomes of both the MitraClip procedure and surgical repair. METHODS: The study population included 264 patients with moderately severe or severe MR assessed by an independent echocardiographic core laboratory. Comparison of safety and effectiveness study endpoints at 30 days and 1 year were made using both intention-to-treat and per-protocol (cohort of patients with MR ≤2+ at discharge) analyses. RESULTS: Pre-existing AF was present in 27% of patients. These patients were older, had more advanced disease, and were more likely to have a functional etiology. Similar reduction of MR to ≤2+ before discharge was achieved in patients with AF (83%) and in patients without AF (75%, p = 0.3). Freedom from death, mitral valve surgery for valve dysfunction, and MR >2+ was similar at 12 months for AF patients (64%) and for no-AF patients (61%, p = 0.3). At 12 months, MR reduction to <2+ was greater with surgery than with MitraClip, but there was no interaction between rhythm and MR reduction, and no difference in all-cause mortality between patients with and patients without AF. CONCLUSIONS: Atrial fibrillation is associated with more advanced valvular disease and noncardiac comorbidities. However, acute procedural success, safety, and 1-year efficacy with MitraClip therapy is similar for patients with AF and without AF.

Duke Scholars

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

April 3, 2012

Volume

59

Issue

14

Start / End Page

1312 / 1319

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Surgical Instruments
  • Severity of Illness Index
  • Risk Assessment
  • Reference Values
  • Mitral Valve Insufficiency
  • Minimally Invasive Surgical Procedures
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Herrmann, H. C., Gertz, Z. M., Silvestry, F. E., Wiegers, S. E., Woo, Y. J., Hermiller, J., … Feldman, T. (2012). Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial. J Am Coll Cardiol, 59(14), 1312–1319. https://doi.org/10.1016/j.jacc.2011.12.023
Herrmann, Howard C., Zachary M. Gertz, Frank E. Silvestry, Susan E. Wiegers, Y Joseph Woo, James Hermiller, Douglas Segar, et al. “Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial.J Am Coll Cardiol 59, no. 14 (April 3, 2012): 1312–19. https://doi.org/10.1016/j.jacc.2011.12.023.
Herrmann HC, Gertz ZM, Silvestry FE, Wiegers SE, Woo YJ, Hermiller J, et al. Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial. J Am Coll Cardiol. 2012 Apr 3;59(14):1312–9.
Herrmann, Howard C., et al. “Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial.J Am Coll Cardiol, vol. 59, no. 14, Apr. 2012, pp. 1312–19. Pubmed, doi:10.1016/j.jacc.2011.12.023.
Herrmann HC, Gertz ZM, Silvestry FE, Wiegers SE, Woo YJ, Hermiller J, Segar D, Heimansohn D, Gray W, Homma S, Argenziano M, Wang A, Jollis J, Lampert MB, Alexander J, Mauri L, Foster E, Glower D, Feldman T. Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial. J Am Coll Cardiol. 2012 Apr 3;59(14):1312–1319.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

April 3, 2012

Volume

59

Issue

14

Start / End Page

1312 / 1319

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Surgical Instruments
  • Severity of Illness Index
  • Risk Assessment
  • Reference Values
  • Mitral Valve Insufficiency
  • Minimally Invasive Surgical Procedures
  • Middle Aged
  • Male